drugset / Trial / NCT01491594
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to accrue subjects to the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 100 mg | Oral |
| Subject | Eltrombopag | Small molecule | 150 mg | Oral |
| Subject | Eltrombopag | Small molecule | 225 mg | Oral |
| Subject | Eltrombopag | Small molecule | 300 mg | Oral |